No, Jardiance and Januvia are NOT the same medication
Jardiance (empagliflozin) and Januvia (sitagliptin) are two completely different diabetes medications that work through distinct mechanisms and belong to different drug classes. They are often used together but serve different therapeutic purposes.
Key Differences
Drug Classes and Mechanisms
Jardiance (empagliflozin) is an SGLT2 inhibitor that works by blocking glucose reabsorption in the kidneys, causing excess glucose to be eliminated in urine 1, 2
Januvia (sitagliptin) is a DPP-4 inhibitor that works by increasing insulin secretion and decreasing glucagon release in response to meals 3
Clinical Benefits Beyond Glucose Control
Jardiance has proven cardiovascular and renal benefits that Januvia does not possess:
Cardiovascular protection: Empagliflozin reduces major adverse cardiovascular events (MACE), cardiovascular death (38% reduction), and heart failure hospitalizations (65% reduction) in patients with established cardiovascular disease 4
Heart failure benefits: Proven efficacy in both HFrEF and HFpEF regardless of diabetes status 5
Renal protection: 39% reduction in composite renal outcomes including progression to end-stage renal disease 4
Januvia (sitagliptin) has demonstrated cardiovascular safety but no significant cardiovascular benefit, and notably, saxagliptin (another DPP-4 inhibitor in the same class) has been associated with increased heart failure hospitalization risk 3, 6
When They Are Used Together
These medications are frequently combined because they complement each other 7, 8, 9:
- They work through different mechanisms, providing additive glucose-lowering effects
- A recent trial showed that adding empagliflozin to patients already on metformin and sitagliptin resulted in significant HbA1c reductions of 0.7-0.8% 9
- The combination is well-tolerated with minimal hypoglycemia risk since neither drug directly stimulates insulin release 1
Clinical Decision-Making
For patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, prioritize Jardiance (empagliflozin) over Januvia 1, 4. The 2025 ADA Standards of Care clearly position SGLT2 inhibitors as preferred agents for patients with these comorbidities due to their proven mortality and morbidity benefits 1.
For patients without cardiovascular or renal disease who need additional glucose lowering beyond metformin, either agent is reasonable, though empagliflozin offers additional benefits including weight loss (intermediate effect) versus weight neutrality with sitagliptin 1, 3.
Important Safety Considerations
Jardiance-specific risks 2:
- Diabetic ketoacidosis (rare but serious; discontinue 3-4 days before surgery)
- Genital mycotic infections
- Volume depletion (monitor in elderly, those on diuretics)
- Fournier's gangrene (extremely rare)
Januvia-specific risks 3:
- Joint pain
- Acute pancreatitis (causal relationship not established)
- Saxagliptin in the same class increases heart failure risk—use DPP-4 inhibitors cautiously in patients at risk for heart failure
Comparative Real-World Evidence
A large Medicare study of over 45,000 older adults showed empagliflozin was associated with 55% lower risk of heart failure hospitalization compared to sitagliptin (HR 0.45) and 32% lower risk of MACE (HR 0.68), with larger absolute benefits in patients with established cardiovascular disease, heart failure, or CKD 10.
Bottom line: These are fundamentally different medications with empagliflozin offering superior cardiorenal protection that extends well beyond glucose control.